ethyl 6-[(hydroxyimino)methyl]-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylate | 264878-97-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: ethyl 6-[(hydroxyimino)methyl]-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylate
• 英文别名: ethyl 6-(hydroxyiminomethyl)-2-(trifluoromethyl)-2H-chromene-3-carboxylate
• CAS: 264878-97-9
• 化学式: C₁₄H₁₂F₃NO₄
• 分子量: 315.249
• InChiKey: NBYOMVRWEBMPMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  68.1
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  ethyl 6-[(hydroxyimino)methyl]-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylate 在 三氟乙酸酐 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.0h， 以40%的产率得到ethyl 6-cyano-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylate
  参考文献：
  名称：

  The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates

  摘要：

  In this manuscript, we report the discovery of the substituted 2-trifluoromethyl-2H-benzopyran-3-carboxylic acids as a novel series of potent and selective cyclooxygenase-2 (COX-2) inhibitors. We provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data. The challenge of a surprisingly long half-life (t(1/2) = 360 h) of the first clinical candidate 1 and human t(1/2) had been difficult to predict based on allometric scaling for this class of highly ppb compounds. We used a microdose strategy which led to the discovery of clinical agents 18c-(S), 29b-(S), and 34b-(S) with human half-life of 57, 13, and 11 h. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.059
• 作为产物：
  描述：

  ethyl 6-formyl-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylate 在 盐酸羟胺 、 sodium acetate 作用下， 以 乙醇 、 水 为溶剂， 反应 18.0h， 以55%的产率得到ethyl 6-[(hydroxyimino)methyl]-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylate
  参考文献：
  名称：

  The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates

  摘要：

  In this manuscript, we report the discovery of the substituted 2-trifluoromethyl-2H-benzopyran-3-carboxylic acids as a novel series of potent and selective cyclooxygenase-2 (COX-2) inhibitors. We provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data. The challenge of a surprisingly long half-life (t(1/2) = 360 h) of the first clinical candidate 1 and human t(1/2) had been difficult to predict based on allometric scaling for this class of highly ppb compounds. We used a microdose strategy which led to the discovery of clinical agents 18c-(S), 29b-(S), and 34b-(S) with human half-life of 57, 13, and 11 h. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.059

文献信息

• Substituted benzopyran derivatives for the treatment of inflammation
  申请人：Carter S. Jeffery

  公开号：US20050049252A1

  公开（公告）日：2005-03-03

  A class of benzopyran, derivatives is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I′ wherein X, A 1 , A 2 , A 3 , A 4 , R, R″, R 1 and R 2 are as described in the specification.

  一类苯并吡喃衍生物被描述为用于治疗环氧合酶-2介导的疾病。特别感兴趣的化合物由公式I'定义，其中X，A1，A2，A3，A4，R，R"，R1和R2如规范中所述。
• The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates
  作者：Jane L. Wang、Karl Aston、David Limburg、Cindy Ludwig、Ann E. Hallinan、Francis Koszyk、Bruce Hamper、David Brown、Matthew Graneto、John Talley、Timothy Maziasz、Jaime Masferrer、Jeffery Carter

  DOI：10.1016/j.bmcl.2010.07.059

  日期：2010.12

  In this manuscript, we report the discovery of the substituted 2-trifluoromethyl-2H-benzopyran-3-carboxylic acids as a novel series of potent and selective cyclooxygenase-2 (COX-2) inhibitors. We provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data. The challenge of a surprisingly long half-life (t(1/2) = 360 h) of the first clinical candidate 1 and human t(1/2) had been difficult to predict based on allometric scaling for this class of highly ppb compounds. We used a microdose strategy which led to the discovery of clinical agents 18c-(S), 29b-(S), and 34b-(S) with human half-life of 57, 13, and 11 h. (C) 2010 Elsevier Ltd. All rights reserved.